Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.
The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.
Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.
In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.
The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.
Adaptimmune Therapeutics (Nasdaq: ADAP) presented data from the Phase 1 SURPASS trial for ADP-A2M4CD8, a novel cancer immunotherapy, at the SITC Conference. Of six heavily pre-treated patients, two achieved confirmed partial responses, with tumor shrinkage observed in five. The company plans to initiate a Phase 2 trial targeting gastroesophageal cancers in the first half of 2021. Preliminary findings suggest ADP-A2M4CD8 may be more effective than earlier versions, with ongoing research into enhanced T-cell manufacturing processes.
Adaptimmune Therapeutics (Nasdaq: ADAP) reported Q3 2020 financial results, revealing revenue growth to $1.2 million, up from $0.2 million a year earlier, driven by collaborations with Astellas and GSK. The company confirmed financial guidance to be funded into 2022, with $78.5 million in cash and total liquidity of $399.9 million. Clinical updates include promising data from Phase 1 trials for liver cancer and synovial sarcoma. Recruitment for ongoing trials is recovering post-COVID-19, with a Phase 2 trial for gastroesophageal cancers expected in H1 2021.
Adaptimmune Therapeutics plc (Nasdaq:ADAP) will report its Q3 2020 financial results and provide a business update on November 5, 2020, before U.S. markets open. The company is recognized for its innovative cancer immunotherapy products, particularly its SPEAR® T-cell platform, engineered to target and eliminate cancer across various solid tumors. A teleconference and webcast will follow the results announcement at 8:00 a.m. EST.
Adaptimmune has announced the early release of the abstract detailing the initial safety and efficacy data from the SURPASS trial involving ADPA2M4CD8, a novel SPEAR T-cell therapy targeting MAGE-A4. The abstract reveals that as of July 16, 2020, five patients have been treated without any dose-limiting toxicities or serious adverse events. Notably, significant responses were observed in patients with esophagogastric junction and head and neck cancers, indicating promising antitumor activity. Full trial results will be presented at the upcoming SITC conference on November 11, 2020.
Adaptimmune Therapeutics presented data from its Phase 1 trial of ADP-A2AFP targeting alpha-fetoprotein (AFP) at the International Liver Congress. One out of four patients treated with five billion or more SPEAR T-cells achieved a complete response, demonstrating acceptable safety despite subsequent disease progression. Notably, a total of nine patients have been treated, with ongoing evaluations of the therapy's effectiveness. Results support further development of ADP-A2AFP for hepatocellular carcinoma (HCC), as the company continues patient enrollment in the expansion phase.
Adaptimmune Therapeutics (Nasdaq: ADAP) reported Q2 2020 financial results, noting significant progress with its ADP-A2M4 therapy for sarcoma. The company raised approximately $244 million through a public offering, ensuring funding into 2022. They received PRIME regulatory support from the EMA for ADP-A2M4 targeting synovial sarcoma and reported responses in multiple solid tumor types during ASCO. The net loss for Q2 was $29.9 million, an improvement over last year's loss of $41.1 million. The company plans to launch ADP-A2M4 in the US in 2022 and continues to advance its clinical trials.
Adaptimmune Therapeutics (Nasdaq: ADAP) announced that the European Medicines Agency (EMA) has granted access to the PRIME initiative for ADP-A2M4, aimed at treating synovial sarcoma. This designation provides enhanced regulatory support to address unmet medical needs. The decision is based on promising Phase 1 trial data showing efficacy and tolerable safety. Adaptimmune has initiated the SPEARHEAD-1 trial for ADP-A2M4, targeting advanced synovial sarcoma and myxoid liposarcoma. The company has also received Orphan Drug Designation from the FDA for related treatments.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) will announce its Q2 2020 financial results and business update on August 6, 2020, prior to U.S. market opening. Following this, a live teleconference and webcast will be hosted at 8:00 a.m. EDT. Investors can access the event via the company's website. Adaptimmune focuses on developing cancer immunotherapy products, utilizing its unique SPEAR® T-cell platform to target solid tumors. The press release also includes forward-looking statements regarding risks and uncertainties that may affect the company's results.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has successfully closed its underwritten public offering of 23,575,000 American Depositary Shares (ADSs) at $11.00 each, raising net proceeds of approximately $242.8 million. The offering included 3,075,000 ADSs from underwriters' full exercise of their option to purchase additional shares. The funds will be utilized to advance clinical trials of their immunotherapies and for general corporate purposes. Cowen and SVB Leerink were joint book-running managers for this offering.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has priced an underwritten public offering of 20.5 million American Depositary Shares (ADSs) at $11.00 each, aiming for a gross size of $225.5 million. The offering will support the advancement of Adaptimmune’s immunotherapy development and general corporate purposes. Underwriters have a 30-day option to purchase an additional 3.075 million ADSs. The offering is expected to close around June 4, 2020, pending customary conditions. Cowen and SVB Leerink are jointly managing the offering.
FAQ
What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is Adaptimmune Therapeutics' primary focus?
What are the key programs of Adaptimmune Therapeutics?
What is afami-cel?
When is afami-cel expected to be commercially available?
What is lete-cel?
What are Adaptimmune’s recent strategic collaborations?
Where are Adaptimmune’s U.S. operations based?
What is Adaptimmune’s approach to cancer treatment?
What are the financial projections for Adaptimmune?
How can one get more information about Adaptimmune’s pipeline and operations?
